A5107961974- Liver Disease Diagnosis and Treatment
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Diseases and Immunity
- Systemic Lupus Erythematosus Research
- HIV/AIDS drug development and treatment
- Organ Transplantation Techniques and Outcomes
- Drug-Induced Hepatotoxicity and Protection
- Gallbladder and Bile Duct Disorders
- Nutrition and Health in Aging
- Renal Transplantation Outcomes and Treatments
- Gastrointestinal motility and disorders
- Intestinal and Peritoneal Adhesions
- HIV/AIDS Impact and Responses
- Lung Cancer Treatments and Mutations
- Biochemical and Molecular Research
- Cardiovascular and Diving-Related Complications
- Pregnancy and Medication Impact
- Abdominal Trauma and Injuries
- Polyomavirus and related diseases
- Liver physiology and pathology
- Poisoning and overdose treatments
- Monoclonal and Polyclonal Antibodies Research
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
2024
Fatebenefratelli Hospital
2006-2021
Ospedale Buon Consiglio Fatebenefratelli
2017-2021
Azienda Ospedaliera Fatebenefratelli e Oftalmico
2011-2016
University of Campania "Luigi Vanvitelli"
2016
Ospedale Antonio Cardarelli
1982-2013
USC Norris Comprehensive Cancer Center
2009
University of Chicago
2008
Azienda di Rilievo Nazionale ed Alta Specializzazione
2006-2007
Ospedale D. Cotugno
2007
Abstract The effect of achieving a sustained virological response (SVR) following interferon-α (IFNα) treatment on the clinical outcomes patients with HCV-related cirrhosis is unknown. In an attempt to assess risk liver-related complications, HCC and mortality in according IFNα treatment, retrospective database was developed including all consecutive HCV-related, histologically proven treated monotherapy between January 1992 December 1997. SVR undetectable serum HCV-RNA by PCR 24 weeks after...
Abstract Background & Aims Cirrhosis ( LC ) and hepatocellular carcinoma HCC are highly prevalent in Europe, with accompanying high mortality rates social costs. As epidemiological data on these diseases scarce, age‐standardized death rate ASDR can serve as an indirect assessment of their burden. Methods We analysed the s for from reported WHO official registries 1970 to 2010, compared over decades. The European Detailed Mortality Database was also used source data. Results In 1970,...
In 1995, the intrafamilial spread of hepatitis C virus (HCV) was evaluated among 1379 household contacts 585 HCV antibody‐positive RNA‐positive subjects (index cases) in Italy. All index cases were patients with histologically proven chronic liver disease. The presence antibodies to (anti‐HCV) assessed by third‐generation enzyme‐linked immunosorbent assay (ELISA); polymerase chain reaction (PCR) used test for RNA. overall anti‐HCV prevalence 7.3% (101/1379); it 15.6% spouses and 3.2% other...
Hepatitis C virus (HCV) vaccines may be able to increase viral clearance in combination with antiviral therapy. We analysed dynamics and HCV-specific immune response during retreatment for experienced patients a phase Ib study E1E2MF59 vaccine. Seventy-eight genotype 1a/1b [relapsers (30), partial responders (16) nonresponders (32) interferon-(IFN)/ribavirin-(RBV)] were randomly assigned vaccine (V:23), Peg-IFNα2a-180-ug/qw ribavirin 1000-1200-mg/qd 48 weeks (P/R:25), or their (P/R + V:30)....
The long-term changes of liver stiffness (LS) in patients who achieve viral clearance after direct-acting anti-HCV therapy remain undefined. We conducted a multicentre prospective study to investigate this aspect. Patients with HCV infection treated DAAs were enrolled from six Italian centres; they underwent clinical, biochemical, ultrasound and transient elastography evaluations before treatment (T0), 12 weeks (SVR12) 24 months (T24) the end therapy. Among 516 consecutive enrolled, 301 had...
Abstract Liver transplantation is one of the main therapeutic options for hepatocellular carcinoma (HCC) occurring in cirrhotic patients; an accurate diagnosis and staging this cancer crucial to selecting candidates treatment. Although best diagnostic strategy debated, guidelines proposed by European Association Study (EASL) are used many centers. We report 2 cases patients with hepatic splenosis, a rare condition that may be misinterpreted as HCC. In conclusion, application EASL first case...
Abstract Background & Aims The proportion of HCV ‐infected patients over age 65 years in Western countries is increasing. This growth and the advent new antiviral therapy bring into question real‐world efficacy safety combination sofosbuvir ( SOF ) simeprevir SMV plus a flat dose 800 mg/d ribavirin RBV elderly with cirrhosis compared to younger patients. Methods Retrospective observational multicentre real‐life investigation study / for duration 12 weeks genotype 1‐infected cirrhosis....
The prevalence and independent predictors of the different macroscopic types hepatocellular carcinoma (HCC) were assessed in 1,073 unselected patients 14 hospitals Italy from May 1996 to 1997. Solitary HCC was most common cancer type (44.6%), followed by multinodular (44.2%), diffuse (8.4%) massive (2.8%) types. After adjustment for influence confounders multiple logistic regression analysis, Child-Pugh grades B C found be (odds ratio, OR, 2.0; 95% confidence interval (CI) = 1.5–2.6) (OR...